Unraveling the Determinants of Protrusion Formation

Table 7

Effects of Rho kinase/myosin inhibitors on the prevalence of factor 4 features^a.

Tukey grouping			Mean	Combination of agents
A			0.599	H1152p (5.02 μM)
A			0.359	Blebbistatin (0.2 μM)
A			0.305	H1152p, ROCK inhibitor (20.2 μM)
A			0.251	Control (PMA + LPA)
A			0.236	Control (untreated)
A	B		−0.064	Blebbistatin (0.8 μM)
	B	C	−0.629	SPC16524, MLC kinase inhibitor (170 μM)
		C	−0.882	SPC16524 (680 μM)

^aMeans with the same letter are statistically indistinguishable at the level 𝑃<0.05.